Parkinson Disease (PD) is the second commonest cause of neurological disability. Approximately, 5.2 million men and women are affected worldwide. Continuous subcutaneous apomorphine (CSAI) represents an alternative treatment option of advanced PD with motor fluctuation. The purpose of this analysis was to estimate the cost-effectiveness of CSAI compared with Levodopa/carbidopa intestinal gel (LCIG), Deep-Brain-Stimulation (DBS) and Standard-of-care (SOC).
Objectives
Parkinson Disease (PD) is the second commonest cause of neurological disability. Approximately, 5.2 million men and women are affected worldwide. Continuous subcutaneous apomorphine (CSAI) represents an alternative treatment option of advanced PD with motor fluctuation. The purpose of this analysis was to estimate the cost-effectiveness of CSAI compared with Levodopa/carbidopa intestinal gel (LCIG), Deep-Brain-Stimulation (DBS) and Standard-of-care (SOC).
Conclusion
Funding the maternal toxoplasma screening saves money and is cost-effective for the society and the Austrian health care system.
PND26 Sensitivity Analysis
Probabilistic sensitivity analysis of 500 trial plots revealed that CSAI is cost effective compared to LCIG in more than 69.6% of the simulations with a willingness to pay of 20,000 £ in the UK and in 98.6% of the simulations in Germany with an willingness to pay threshold of 20,000 €; versus DBS in 25.8% (33%) and versus SOC in 98.7% (16.6%) of all simulations (Fig. 3 
Methods
We developed a Markov-Model to simulate the long-term consequences, disease progression (Hoehn&Yahr-stages 3-5, percentage of waking-time in the OFF-state), complications and adverse-events. The model is adopted based on models which have been published for the UK and Sweden. Complications are different for the alternatives (e.g. pump problems in case of LCIG, temporary/permanent complications in case of DBS). Moderate and severe adverse-events (e.g. motor fluctuation, dyskinesia, nausea, dizziness, hallucination, skin problems, depression, anxiety) and death were included. Including 25 health-states, the model comprises moderate and severe health conditions. Probabilities derived from RCT and open-label studies. Direct costs (2012) were estimated from the perspective of the national health care systems.
Source: developed by IPF 
Cohort definition
The model cohort comprises PD patients aged 50 years or older with Hoehn&Yahr (H&Y) stages 3, 4 or 5 experiencing more than 50% of wakingtime (14 hour) in the OFF state at treatment initiation. After treatment initiation with CSAI, LCIG or DBS an improvement in health states in the following cycle may arise; or patients continue SOC. During different therapeutic alternatives adverse events or complications may arise. Due to intolerable adverse events, patients have the opportunity to switch to an alternative treatment. Patients receiving first-line CSAI or LCIG switch to DBS and patients after a DBS either start or increase SOC medication.
Source: IPF own calculations 
Ressource use and costs
The cost assessment is based on the assignment of costs to the health states. The costs of each health state are determined by the resource utilisation associated with a health state. Resource use (e.g. the type and frequency of medical goods and services rendered to the patient) and monetary value (prices, tariffs and/or opportunity costs) for each unit of medical goods and services were used to calculate the total direct costs. In order to estimate the cost of aPD and related costs including the AE and complication costs in the UK and Germany only direct costs were included in the analysis. Health state costs (H&Y and OFF stages) were calculated based on the resource use data of Findley et al. (2011) , which were multiplied with national unit costs.
